Impel NeuroPharma to Participate in Upcoming Virtual Investor Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/22/2026

1. WMT
2. ROST
3. AAP
4. SPY
5. NVDA

6. AVGO
7. SPCX
8. HD
9. BJ
10. BABA

Get Alerts IMPL Hot Sheet

Price: $0.24 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

SEATTLE, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that Adrian Adams, Chairman and Chief Executive Officer, will participate in the following upcoming investor conferences.

Cowen & Co. 42nd Annual Health Care ConferenceFormat: Fireside ChatDate: Monday, March 7, 2022Time: 1:30 p.m. ET

Oppenheimer 32nd Annual Healthcare ConferenceFormat: Company PresentationDate: Thursday, March 17, 2022Time: 2:40 p.m. ET

A live webcast of the event will be available on the Investors section of the Impel NeuroPharma website at https://investors.impelnp.com/. A replay of the presentation will be available on the website for 90 days.

About Impel NeuroPharmaImpel NeuroPharma, Inc. is a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. Impel offers and is developing treatments that pair its proprietary Precision Olfactory Delivery (POD®) technology with well-established therapeutics. In addition to Trudhesa™ (dihydroergotamine mesylate) nasal spray, which is approved in the United States for the acute treatment of migraine with or without aura in adults, Impel is also developing INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.

Contact:

Media Relations:Melyssa WeibleElixir Health Public RelationsPhone: (1) 201-723-5805Email: [email protected]

Investor RelationsChristina TartagliaStern Investor RelationsPhone: 212-362-1200Email: [email protected]